Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

Junaid Abdulghani, Wafik S. El‐Deiry(Fox Chase Cancer Center)
PLoS ONE
September 26, 2013
Cited by 46


Related Papers